- Aytu BioPharma ( NASDAQ: AYTU ) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,.
- The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429.
- Gross proceeds are expected to be ~$10M.
- Offer is expected to close on Aug.11.
- Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.
For further details see:
Aytu BioPharma plunges on pricing $10M stock and warrants offering